Drug Database
AL

albumin (Zenalb)

✓ Approved

Kedrion · Cell-based Therapies · Cell-based Therapies

What is albumin?

albumin is a cell-based therapies developed by Kedrion. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesZenalb
CompanyKedrion
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Kedrion

Therapeutic Indications

albumin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved

Related Research Articles

PubMedBMC neurology2026-11-11

Targeted biologics in muscle strength restoration and corticosteroid sparing for patients post-myasthenic crisis.

Wang Yuan Y, Jin Lei L, Huan Xiao X, Chen Ran R et al.

Myasthenic crisis (MC) represents a life-threatening condition in patients with myasthenia gravis (MG). Despite a substantial reduction in in-hospital mortality for MC, full restoration of muscle strength and quality of life usually requires months or years. It remains unknown whether the sequential use of targeted biologics improves clinical outcomes in patients post-MC compared with the standard of care (SOC). We prospectively followed patients from MC through 6 months post-discharge between November 2018 and November 2025. We then stratified patients into subgroups according to the use of either biologics-based therapy (C5 inhibitors, FcRn antagonists, or rituximab) (BIO) or SOC. The primary endpoint was the Myasthenia Gravis Foundation of America-quantitative MG (MGFA-QMG) score at 6 months after discharge. Secondary outcomes included Myasthenia Gravis Activities of Daily Living (MG-ADL), steroid dose, immunosuppressant (IS) use, cumulative steroid exposure, minimal symptom expression (MSE), and residual symptom burden. At 6 months after discharge, the BIO group (n = 56) had a lower MGFA-QMG score than the SOC group (n = 56) (4.51 ± 4.03 vs 6.28 ± 4.72; P = 0.038). Meanwhile, the BIO group required a lower dose of oral corticosteroid (14.74 ± 10.24 vs 21.96 ± 12.87 mg/day; P = 0.004), lower cumulative steroid burden (158.13 ± 64.71 vs 209.24 ± 96.81 mg/day·month; P = 0.001), and had a lower proportion of IS use (47.3% vs 67.9%; P = 0.028). MSE was achieved in 56.86% in the BIO and 60.38% in the SOC group, respectively. Targeted biologics were associated with better objective muscle strength and reduced corticosteroid and IS use after MC, although no significant between-group difference was observed in MG-ADL. A substantial proportion of patients in both groups continued to have residual symptoms at 6 months.

PMID 43009845
Read full article →
PubMedMedicine2026-11-11

Association between nursing assessment indicators and adverse outcomes in hospitalized patients with atrial fibrillation: A retrospective observational study.

Han Jie J, Liu Siyu S, Li Nan N, Zhang Ruiqin R

This retrospective observational study examines the association between routinely collected admission nursing assessment indicators and in-hospital adverse outcomes among hospitalized patients with atrial fibrillation (AF). A total of 312 hospitalized patients with AF admitted to a tertiary teaching hospital between January 2021 and December 2024 were included. The Morse Fall Scale, Barthel Index, Nutritional Risk Screening 2002 (NRS-2002), and Braden Scale were assessed within 24 hours of admission. Clinical characteristics, vital signs, and laboratory data were extracted from electronic medical records. The composite adverse outcome comprised in-hospital death, unplanned intensive care unit admission, worsening heart failure requiring treatment escalation, major bleeding requiring medical intervention, or thromboembolic events. Univariable and multivariable logistic regression analyses were used to examine associations with the composite outcome. Among 312 patients, 68 (21.8%) experienced at least one adverse outcome. In the adjusted analysis, a higher Morse Fall Scale score was associated with higher odds of adverse outcomes (OR 1.031, 95% CI 1.012-1.051; P = .002), whereas a higher Barthel Index score was associated with lower odds (OR 0.978, 95% CI 0.961-0.995; P = .012). A higher NRS-2002 score was associated with higher odds (OR 1.376, 95% CI 1.083-1.748; P = .009), and a higher serum albumin level was associated with lower odds (OR 0.953, 95% CI 0.920-0.988; P = .010). AF type and Braden Scale score were not independently associated with the composite outcome after adjustment. Admission nursing assessments of fall risk, functional status, and nutritional risk, together with serum albumin, were independently associated with in-hospital adverse outcomes. These results support their use as complementary markers of vulnerability and for closer clinical surveillance, but they do not establish causality or justify changing guideline-directed AF treatment. Prospective multicenter studies are required before these measures can be incorporated into validated clinical decision tools.

PMID 43012841
Read full article →
PubMedFrontiers in endocrinology2026-11-11

UACR adjustment attenuates associations of selected routine blood markers with documented diabetic retinopathy more than eGFR adjustment: a cross-sectional study in type 2 diabetes.

Zhang Jing J, Xu Mingliang M, Xiong Baoyi B, Luo Baohua B et al.

Studies of routine blood markers and diabetic retinopathy often adjust for estimated glomerular filtration rate (eGFR), although albuminuria captures a different aspect of kidney damage. We compared these associations under eGFR and urinary albumin-to-creatinine ratio (UACR) adjustment. We analyzed 8,159 adults hospitalized with type 2 diabetes from January 2020 to March 2026. Primary exposures were serum albumin, total bilirubin, fibrinogen and the FIB-4 index. Four models were fitted in a fixed complete-case sample, with additional adjustment for eGFR, log UACR, or both. The outcome was documented diabetic retinopathy (DR), based on ophthalmological assessment and discharge diagnosis; DR = 0 included unassessed patients without a DR diagnosis. Prevalence ratios were estimated by marginal standardization. Among 3,978 complete-case patients, 958 (24.1%) had documented DR. Adjustment for log UACR attenuated the serum albumin association more than adjustment for eGFR (73.3% versus 34.3%; difference 38.9 percentage points, 95% CI 30.7 to 49.0) and moved the fibrinogen estimate close to one. Binary albuminuria produced substantially less attenuation than continuous log UACR. Multiple imputation supported the renal-adjustment comparison, although the albumin interval included the null after mutual renal adjustment. Serum albumin remained associated with documented DR after restriction to eGFR ≥90 mL/min/1.73 m2 (prevalence ratio 0.762, 95% CI 0.649 to 0.873), whereas no clear evidence of an eGFR association was observed within this stratum (0.981, P = 0.823). Conclusions: In this single-center inpatient cohort, eGFR and UACR adjustment yielded different estimates for the studied blood-marker associations with documented DR. Attenuation denotes proportional reduction in the absolute log prevalence-ratio estimate, not a causal proportion explained. Dichotomizing UACR discarded information and reduced attenuation in these models.

PMID 43011024
Read full article →
PubMedJournal of biological engineering2026-11-11

Engineering an agrowaste-based multilayer bio-encapsulation system for sustained nutrient release and microbial biotransformation of chlorinated solvents.

Yang Dun-Sheng DS, Shen Meng-Wei MW, Huang Ya-Ling YL, Lin You-Ping YP et al.

Trichloroethylene (TCE), a known carcinogen, is denser than water, which explains its deep presence in groundwater. Limitations on long-term supplies of TCE degraders and nutrients often led to TCE dichlorination failures in the field. This study presents the development and evaluation of an agrowaste-based multilayer bioencapsulation system designed to prolong microbial activity and enhance nutrient availability for a more favorable TCE-dechlorination environment. TCE-degrading consortia were integrated with a nutrient-rich core derived from recycled fermented agrowastes and encapsulated within a structurally reinforced sodium alginate matrix to form bio-pellets. The acclimated microbial community exhibited a degradation rate constant of 0.33 day⁻¹, with confirmed transformation of TCE into dichloroethylene and vinyl chloride, indicating active reductive dechlorination pathways. Characterization of the encapsulated system revealed a nutrient profile of 410.4 ± 29.7 mg TOC g⁻¹, 9.1 ± 0.2 mg TN g⁻¹, and 20.5 ± 0.7 mg TP g⁻¹, which enabled sustained nutrient release to support microbial metabolic functions. Column reactor experiments demonstrated that the multilayer structure maintained physical integrity and functional stability for more than 74 days. The system achieved a total TCE removal efficiency of 98.5%, reducing concentrations from 600 mg L⁻¹ to 9.1 mg L⁻¹, while effectively alleviating mass transfer limitations commonly observed in non-encapsulated systems. Although microbial activity induced localized acidification, the incorporation of natural buffering capacity helped maintain system stability. These results demonstrate that the proposed bio-encapsulation platform provides a framework for integrating material design with microbial function, offering promising applications in environmental biotechnology and bioprocess engineering.

PMID 43010045
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-11-11

A Novel Immunosuppressive Effector Functions as a Bio-Adjuvant to Enhance the Activity of Bacillus Thuringiensis and Chemical Insecticides.

Liu Zhiyu Z, Chen Feng F, Wan Liting L, Chen Li L et al.

Host innate immunity is a major barrier to microbial infection and often limits the efficacy of biological and chemical pest-control agents. While microbial immunosuppressive effectors have been described, whether quorum-sensing systems coordinate virulence and immune suppression during host infection remains largely unknown. We demonstrated that the PlcR-PapR quorum-sensing system acts as a master regulator that promotes both processes (virulence and immune suppression) to enhance Bacillus thuringiensis (Bt) pathogenicity. During infection, PlcR-PapR signaling induces production of the heptapeptide PapR7, which activates expression of patatin-like protein PisP, a previously uncharacterized and widely conserved protein. PisP suppresses host immunity by inhibiting nuclear translocation of the transcription factor DAF-16, thereby attenuating the expression of antimicrobial defense genes. Consistent with this mechanism, Bt strains overexpressing pisP display enhanced virulence against both nematodes and insect hosts. Importantly, exogenous PisP markedly potentiates the activity of Bt Cry5Ba toxin and several commercial chemical insecticides, enabling effective pest control at reduced doses. Together, these findings reveal a quorum-sensing-controlled mechanism that links virulence regulation to immune suppression during Bt infection and identify PisP as a conserved Bt-encoded immunosuppressive effector with strong potential as a bio-adjuvant for improving the efficacy and sustainability of biological and chemical pest-management strategies.

PMID 43010775
Read full article →
PubMedMedicine2026-11-11

The C-reactive protein-albumin-lymphocyte (CALLY) index in early hospital presentation and intravenous thrombolysis in acute ischemic stroke: A retrospective study.

Basa Kalafat Ayşe Fethiye AF, Güner Muhammed M, Olcay Elif Gizem EG, Karadeniz Feyza F et al.

The C-reactive protein-albumin-lymphocyte (CALLY) index reflects systemic inflammation and immune and nutritional status. We investigated whether admission CALLY was associated with early hospital presentation or receipt of intravenous thrombolysis (IVT) in adults with acute ischemic stroke. This single-center retrospective study included 197 adults with acute ischemic stroke admitted between September 2018 and September 2024. All 98 patients who received IVT were included; 99 non-thrombolyzed controls were selected by computer-generated random sampling from a pool constructed using group-level frequency matching. CALLY was calculated as albumin (g/L) × lymphocyte count (×109/L)/[C-reactive protein (mg/L) × 10]. Early presentation was defined as onset-to-door time ≤4.5 hours. Multivariable logistic regression adjusted for age, sex, and National Institutes of Health Stroke Scale (NIHSS) score assessed associations of ln(CALLY) with early presentation and receipt of IVT. Patients who received IVT had higher NIHSS scores (median, 7 vs 1; P < .001) and lower CALLY values (median, 1.37 vs 2.64; P = .050); however, the CALLY difference was not significant after multiplicity correction (q = 0.122). CALLY was inversely correlated with NIHSS score (Spearman ρ = -0.29; P < .001). After adjustment, ln(CALLY) was not associated with receipt of IVT (adjusted odds ratio = 1.34; 95% confidence interval = 0.98-1.82; P = .063). Its borderline association with early presentation (adjusted odds ratio = 1.34; 95% confidence interval = 1.02-1.77; P = .036) was not consistent across sensitivity analyses. CALLY did not differ significantly between early and late presenters (P = .100). Lower CALLY values among patients receiving IVT were largely explained by greater stroke severity. No consistent independent association was found between CALLY and either outcome. These findings do not support using CALLY to guide thrombolytic decision-making.

PMID 43012800
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about albumin